All Trials

STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (SPARK)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic clear-cell RCC showing oligoprogression (1–3 lesions) after prior anti–PD-1/CTLA-4 therapy receive continued nivolumab plus PULSAR stereotactic adaptive radiotherapy to all progressing sites, with one lesion also injected intratumorally with the STING agonist IMSA101 (2′3′-cGAMP analog activating TMEM173 to induce type I IFNs) over five doses. Requires at least one safely injectable non-lung lesion; excludes progressive ultracentral/central chest lesions.

ClinicalTrials.gov ID: NCT06601296

A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic clear cell RCC, VEGF TKI–naive (allowing ≤1 prior line of cytokine or ICI), are randomized to pazopanib plus the pan–HDAC inhibitor abexinostat versus pazopanib alone. Abexinostat (HDAC class I/II inhibitor that may enhance VEGF-TKI sensitivity via HIF-1α downregulation) is given intermittently with continuous daily pazopanib; crossover to the combination is allowed at progression from the control arm.

ClinicalTrials.gov ID: NCT03592472

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adults with untreated recurrent, persistent, or metastatic cervical cancer (squamous, adeno, or adenosquamous) not amenable to curative therapy, ECOG 0–1, and no prior checkpoint inhibitor or systemic therapy for metastatic disease. Patients receive induction lorigerlimab (MGD019), a bispecific PD-1/CTLA-4 checkpoint inhibitor (DART IgG4) given IV every 3 weeks, with efficacy assessed by RECIST and close safety monitoring for immune-related AEs.

ClinicalTrials.gov ID: NCT05475171

A Biomarker Study of the Wee1 Inhibitor Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study of azenosertib (ZN‑c3), an oral WEE1 kinase inhibitor that abrogates the G2/M checkpoint and increases replication stress, in adults with recurrent or persistent uterine serous carcinoma after prior platinum therapy (MSI-H/dMMR patients should have received or be ineligible for PD-1/PD-L1 therapy). Requires measurable disease and biopsiable lesion for paired biopsies; assesses antitumor activity and biomarker correlations, with intermittent oral dosing on Days 1–5, 8–12, and 15–19 each cycle.

ClinicalTrials.gov ID: NCT06369155

RESOLVE: letRozole abEmaciclib combinationS in endOmetriaL and oVarian cancEr: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination With Metformin, Zotatifin and Gedatolisib

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent/metastatic or treatment‑resistant endometrial cancer (primarily ER+) or low‑grade serous ovarian/fallopian tube/peritoneal carcinoma (ER+ preferred; ER‑ allowed in LGSOC) receive abemaciclib with letrozole, alone or combined with agents targeting PI3K/mTOR/DNA‑PK (samotolisib/LY3023414), pan‑class I PI3K/mTORC1/2 (gedatolisib), translational control via eIF4A (zotatifin), or metabolic/AMPK pathways (metformin). Most cohorts require ECOG 0–1, measurable disease, adequate organ function, and endocrine sensitivity markers; one cohort allows prior CDK4/6 inhibitor exposure.

ClinicalTrials.gov ID: NCT03675893

A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study of lifileucel, an autologous tumor-infiltrating lymphocyte (TIL) therapy delivered after lymphodepleting chemotherapy and high‑dose IL‑2, in adults with advanced endometrial carcinoma (including carcinosarcoma) who have progressed after platinum chemotherapy and anti–PD‑1/PD‑L1 therapy, with at least one resectable lesion for TIL manufacture and one measurable lesion. Excludes uterine sarcomas and requires ECOG 0–1 and adequate organ function.

ClinicalTrials.gov ID: NCT06481592

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adult women with recurrent/progressive gynecologic cancers (e.g., endometrioid, mucinous ovarian, high-grade serous ovarian, others) harboring MAPK-pathway alterations (RAS activation/mutation, BRAF class I–III mutation, and/or NF1 loss), ECOG 0–1, and prior systemic therapy; excludes prior RAF/MEK inhibitor exposure and LGSOC. Treatment is oral avutometinib (dual RAF/MEK “clamp”) plus defactinib (FAK inhibitor).

ClinicalTrials.gov ID: NCT05512208

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adult women with measurable recurrent or persistent uterine serous carcinoma after prior platinum chemotherapy and PD-(L)1 therapy (HER2-positive must have received HER2 therapy if eligible) receive oral azenosertib (ZN‑c3), a selective WEE1 kinase inhibitor. Single-arm study excludes prior WEE1/ATR/CHK1/2 inhibitors; efficacy assessed by RECIST with attention to GI and hematologic toxicities.

ClinicalTrials.gov ID: NCT04814108

A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Biomarker-driven study in adults with recurrent/metastatic high‑grade endometrial cancer post platinum and anti–PD-(L)1, testing the CHK1/CHK2 inhibitor prexasertib (ACR‑368) either alone in OncoSignature-positive tumors or with ultra–low‑dose gemcitabine in OncoSignature‑negative or unselected patients. Requires measurable disease, ECOG 0–1, adequate organ function; key exclusions include symptomatic brain mets and prior CHK1 inhibitor exposure.

ClinicalTrials.gov ID: NCT05548296

An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable recurrent or metastatic HPV16-positive, PD-L1 CPS ≥1 HNSCC (non-nasopharyngeal), treatment-naïve in the R/M setting, are randomized to pembrolizumab alone versus pembrolizumab plus BNT113, an investigational HPV16 E6/E7 mRNA lipoplex vaccine designed to activate dendritic cells and elicit HPV16-specific T-cell responses. Requires measurable disease and available tumor tissue; prior systemic therapy for locally advanced disease allowed if completed >180 days before randomization.

ClinicalTrials.gov ID: NCT04534205